FDA Accepts Biomedica MC Investigational New Drug Filing for ClotFoam®
ClotFoam is the leading agent of a portfolio of hemostatic products based on its proprietary “CLOT” technology. This next generation of hemostatic sealants funded by NIH and the US Army was originally conceived to control severe hemorrhage without need of compression. Products derived from the Clot technology represent a quantum leap in the treatment of hemorrhage. - September 09, 2013
Press Releases 1 - 1 of 1